NCT05330078View on ClinicalTrials.gov

Examining the Therapeutic Potential of Botulinum Toxin Type A in the Treatment of Keloids

EARLY_PHASE1Active, not recruitingINTERVENTIONAL
Enrollment

10

Participants

Timeline

Start Date

March 11, 2022

Primary Completion Date

January 31, 2032

Study Completion Date

January 31, 2032

Conditions
Keloid
Interventions
DRUG

Botulinum toxin type A

Participants will receive Botulinum toxin type A 5 units / cm3 with injections of 0.2mL spaced evenly 1cm apart within the treatment area (half of the keloid). Each treatment will consist of a maximum of 2 mL (10 injection sites, 50 unit total) of the study drug. Patients will undergo 3 treatments, 6 weeks apart.

DRUG

Vehicle

Participants will receive saline injections of 0.2mL spaced evenly 1cm apart within the placebo area (half of the keloid). Each treatment will consist of a maximum of 2 mL (10 injection sites) of the vehicle control (saline). Patients will undergo 3 treatments, 6 weeks apart.

Trial Locations (1)

92122

University of California San Diego, San Diego

All Listed Sponsors
lead

University of California, San Diego

OTHER